Medtronic MiniMed 670G (first hybrid closed loop)
Medtronic
The first FDA-approved commercial hybrid closed-loop system. It automatically adjusted basal insulin using Guardian Sensor 3 but still required meal boluses and calibrations, with a fixed 120 mg/dL target. It is now superseded by newer Medtronic systems, but leaving it out erases the device that opened the commercial AID era.
The scorecard
Achieved ~70-72% TIR in real-world T1D cohorts (70.4% in the 123,355-user US registry, 72% in the 14,899-user EU cohort), at the international 70% target but well below the 780G ~76% anchor; corrected up from 58 since real-world data clearly exceeds that.[5]
Achieved time-below-70 of ~2.2-2.4% (2.2% in the 123,355-user US cohort, 2.4% in the EU cohort), consistent low-protection of a hybrid loop without auto-correction boluses.[5]
Automated basal modulation only: users still bolused for meals, performed calibrations, and had no automated correction boluses.[3]
Achieved GMI of 7.0% in both the US (N=123,355) and EU (N=14,899) real-world T1D cohorts, tracking a few points below the TIR score as expected.[5]
Achieved ~70-72% TIR with ~2.2% time-below-70 in the 123,355-user US cohort implies moderate variability for a first-gen hybrid loop; CV not published, and frequent Auto Mode exits add swing, so scored conservatively.[5]
Temporary targets helped, but exercise still required user planning and manual carbohydrates/bolus adjustments.[3]
Fixed 120 mg/dL Auto Mode target and fewer user-tunable settings than modern AID systems.[3]
Superseded by later Medtronic systems; included here mainly for historical and evidence-lineage completeness.[4]
An older tubed pump — a bulkier body, tubing and a separate handset make it the least discreet of current systems.
Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.
Editor’s take
The 670G should not rank highly in 2026, but it absolutely belongs in the scientific map. It was the first commercial proof that a pump, CGM and onboard algorithm could run safely at home at scale. The whole modern AID category stands on this rung.
The full picture
Why it still matters
MiniMed 670G is no longer the system to recommend first, but it was the first commercial hybrid closed loop. Its Auto Mode adjusted basal insulin every few minutes from Guardian Sensor 3 readings, while users still announced meals and gave boluses.
The limitations are as important as the success: fixed target, calibration burden, Auto Mode exits, no automated correction boluses, and limited customization. Those limits explain why later systems such as 780G, Control-IQ, Omnipod 5 and iLet matter.
Coming soon
ETA · Superseded by MiniMed 770G/780G and other modern AID systems
Sources
- [1]Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes · peer-reviewed · 2017-03-01 — Pivotal in-home MiniMed 670G hybrid closed-loop study.
- [2]Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes · peer-reviewed · 2019-01-01 — Pediatric study: TIR 56.2% to 65.0%, HbA1c 7.9% to 7.5%, no severe hypoglycemia or DKA during study phase.
- [3]FDA PMA P160017/S031 MiniMed 670G System · regulatory · 2018-06-21 — FDA expansion to people with T1D aged 7 years and older.
- [4]Medtronic receives FDA approval for world's first hybrid closed-loop system · manufacturer · 2016-09-28 — Manufacturer announcement for original FDA approval age 14+.
- [5]Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States (N=123,355; TIR 70.4%, GMI 7.0%, TBR<70 2.2%) · peer-reviewed · 2022-04-12
- [6]Real-world performance of the MiniMed 670G system in Europe (N=14,899; TIR 72.0%, GMI 7.0%, TBR<70 2.4%) · peer-reviewed · 2021-05-01
- [7]Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch (N=3,141; Auto Mode TIR 73.3%, TBR<70 2.1%) · peer-reviewed · 2018-08-30
- [8]Real-world performance of hybrid closed loop across the lifespan: HCL use declines to ~49-56% in youth/young adults by 12 months (Auto Mode exit/discontinuation caveat) · peer-reviewed · 2021-06-09